TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11455143
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (topical corticosteroid + barrier cream)
Study: 2590625
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid
Study: 11455143
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (fourth patch)
Study: 2513047
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blockers (active treatment)
Study: 785427
Drug: Adsorbed surface-antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adsorbed surface-antigen influenza vaccine
Study: 24021959
Drug: Selegiline transdermal
Normalized name: Selegiline Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline transdermal system (STS) 6 mg/24h
Study: 21240530
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (undercutting laminectomy augmented with transpedicular-instrumented fusion)
Study: 11524464
Drug: Mylan extended-release
Normalized name: hylan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mylan extended-release phenytoin sodium capsules with food
Study: 31446180
Drug: Genotype analysis
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype analysis for NUDT15, FTO, and TPMT variants; patients heterozygous for any variant received 50 mg azathioprine equivalents, homozygous patients received alternative drugs; those without variants and non-genotyping group received 50 mg azathioprine equivalents with dose escalation.
Study: 31446180
Drug: Non-genotyping group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-genotyping group (no genotype analysis); received 50 mg azathioprine equivalents followed by dose escalation.
Study: 31446180
Drug: Maximum dose
Normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maximum dose of thiopurines
Study: 18638649
Drug: Therapy as
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy as usual
Study: 22094353
Drug: Atorvastatin (AT,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (AT, n=17)
Study: 24007717
Drug: Hormone Therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone Therapy (HT, n=34)
Study: 24007717
Drug: Hormone Therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone Therapy plus Atorvastatin (HT+AT, n=36)
Study: 10930822
Drug: Atorvastatin (AT)
Normalized name: AT 10
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin (AT)
Study: 3536262
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy plus salmon calcitonin 100 MRC units daily for 3 weeks (Group II)
Study: 3536262
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy alone (Group I)
Study: 1454457
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg d-amphetamine
Study: 24721024
Drug: Procedural sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procedural sedation analgesia (SA) with ketamine 1 to 2 mg/kg intravenously
Study: 11465654
Drug: Lisinopril and
Normalized name: lisinopril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril and Losartan
Study: 9629934
Drug: Less intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less intensive treatment programs
Study: 2896556
Drug: Atenolol (beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (beta 1-selective blocker)
Study: 3993547
Drug: Propranolol (nonselective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (nonselective beta-blocker)
Study: 30289485
Drug: Dapivirine vaginal
Normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapivirine vaginal ring (25 mg DPV)
Study: 25615629
Drug: Prefix 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prefix 750 (750 μg/cm(3) granules)
Study: 25615629
Drug: Prefix 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prefix 150 (150 μg/cm(3) granules)
Study: 24199982
Drug: Conventional periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional periodontal treatment (CPT) and homeopathic medicine (HM)
Study: 24199982
Drug: Conventional periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional periodontal treatment (CPT)
Study: 21606877
Drug: Cooling collar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooling collar from the start (CC)
Study: 21606877
Drug: Cooling collar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooling collar replaced at 30‐min intervals (CC(replaced))
Study: 21214352
Drug: Cooling collar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooling collar (CC)
Study: 18342185
Drug: Trospium 60
Normalized name: trospium 60 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trospium 60 mg QD
Study: 16540862
Drug: Chiropractic care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiropractic care without physical therapy or modalities
Study: 16540862
Drug: Medical care
Normalized name: benzethonium Medicated Liquid Soap [Bedside-Care]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical care with physical therapy
Study: 16540862
Drug: Chiropractic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiropractic and physical therapy
Study: 12653262
Drug: Tacrolimus and
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus and low-dose prednisolone
Study: 1347204
Drug: Pipecuronium 0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pipecuronium 0.06 mg.kg-1
Study: 1347205
Drug: Vecuronium 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.2 mg.kg-1
Study: 29789925
Drug: CYP2D6 gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: CYP2D6 gene rs28371725 CC and CT genotypes in PPE
Study: 23217093
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (augmented by recommendation for counseling center and physician information)
Study: 16394300
Drug: Intravenous paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel
Study: 16394300
Drug: Intravenous paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous paclitaxel plus cisplatin
Study: 10848537
Drug: Glibenclamide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (5 mg po)
Study: 10848537
Drug: Insulin (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (0.3 mU.kg(‐1).min(‐1) iv)
Study: 10848537
Drug: Nicorandil (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (40 mg)
Study: 10848537
Drug: Glibenclamide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (5 mg) or Nicorandil (40 mg) or Glibenclamide and Nicorandil
Study: 8869800
Drug: Prophylactic or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic or pre‐emptive therapy
Study: 8869800
Drug: Empiric therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric therapy for febrile episodes
Study: 8869800
Drug: Pre‐emptive therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre‐emptive therapy
Study: 1323974
Drug: Recombinant interferon
Normalized name: Recombinant Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant interferon beta serine (12 x 10(6) U, nasal drops, three times daily for 4.3 days)
Study: 1323974
Drug: Placebo (nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (nasal drops, three times daily for 4.3 days)
Study: 29775959
Drug: Cigarettes with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarettes with 15.8 mg/g nicotine
Study: 29775959
Drug: Cigarettes with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarettes with 5.2 mg/g nicotine
Study: 29775959
Drug: Cigarettes with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarettes with 1.3 mg/g nicotine
Study: 29775959
Drug: Cigarettes with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarettes with 0.4 mg/g nicotine
Study: 22824768
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation and anti-H. pylori therapy (Group I)
Study: 14613288
Drug: Etanercept 25
Normalized name: etanercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 25 mg subcutaneously twice weekly for 24 weeks
Study: 9659650
Drug: Carbetocin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbetocin (100 micrograms intravenous injection)
Study: 9659650
Drug: Oxytocin (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (continuous 16 hour infusion)
Study: 2534405
Drug: D-sulpiride at
Normalized name: sulpiride
DrugBank: Sulpiride (DB00391)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-sulpiride at 0.05 mg/kg per min
Study: 2534405
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic factor (ANF) + D-sulpiride at the same doses
Study: 786773
Drug: Intravenous metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metoclopramide (M)
Study: 25126957
Drug: Melatonin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (6 mg daily for 40 days)
Study: 21971959
Drug: Early stage
Normalized name: SALICYLIC ACID 0.14 mg TOPICAL PATCH [Peace Out Early Stage Acne Dot]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early stage cervical and endometrial cancer treatment
Study: 16990976
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin (20 IU injection)
Study: 16990976
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate ointment (300 mg of 0.2% applied three times daily for 30 days)
Study: 8633687
Drug: Divalproex, 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divalproex, 750 mg/day for 2 days, then 1,000 mg/day on days 3-5, adjusted as clinically indicated for 21 days
Study: 8633687
Drug: Divalproex, serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divalproex, serum levels >= 125 micrograms/ml
Study: 1538042
Drug: Pentoxifylline (Trental)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (Trental) 400 milligram tablets three times daily
Study: 18810239
Drug: Baseline serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline serum urate levels (measured in mg/dl)
Study: 9033440
Drug: Bambuterol 20
Normalized name: bambuterol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bambuterol 20 mg nocte (B20)
Study: 9033440
Drug: Bambuterol 10
Normalized name: bambuterol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bambuterol 10 mg nocte (B10)
Study: 9033440
Drug: Terbutaline 3
Normalized name: terbutaline 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline 3 mg t.i.d. (T)
Study: 20689457
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution (P)
Study: 8509565
Drug: Flosequinan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flosequinan (100 mg once daily, n = 93)
Study: 3549837
Drug: Milrinone (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milrinone (all doses)
Study: 3549837
Drug: Milrinone (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milrinone (high dose)
Study: 20678799
Drug: Monthly intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly intravitreal injections of 0.5 mg ranibizumab
Study: 20678799
Drug: 3 monthly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3 monthly injections followed by dosing as needed (PRN)
Study: 16556673
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg IN buserelin twice a day (group D)
Study: 16556673
Drug: 10,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10,000 IU hCG followed by vaginal administration of micronized progesterone (3x 200 mg/day) (group A)
Study: 10902992
Drug: M =
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: M = 12 mg iron + 209 kJ
Study: 8263313
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg venlafaxine
Study: 3032828
Drug: Dietary fibre
Normalized name: Fiore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary fibre supplement of 7.3 g per day
Study: 31429603
Drug: Asthmatic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asthmatic and diabetic patients using budesonide (up to 825 mcg)
Study: 22350703
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg rectal diclofenac (reduced to 25 mg for patients weighing <50 kg)
Study: 22350703
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (saline infusion without diclofenac)
Study: 16023511
Drug: MIT therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIT therapy
Study: 16023511
Drug: No MIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: No MIT therapy
Study: 12481892
Drug: Amifostine (AMI)
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amifostine (AMI) 910 mg/m2 in 15 min infusion preceding MEL 200 mg/m2
Study: 9637805
Drug: Rectal diazepam
Normalized name: diazepam Rectal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal diazepam gel (0.2 to 0.5 mg/kg based on age)
Study: 9637805
Drug: Rectal diazepam
Normalized name: diazepam Rectal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal diazepam gel
Study: 334206
Drug: Buprenorphine 0.6
Normalized name: buprenorphine 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 0.6 mg
Study: 31629348
Drug: CES-HGel (carbohydrate-electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: CES-HGel (carbohydrate-electrolyte solution with sodium alginate and pectin)
Study: 31629348
Drug: CES-Std (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: CES-Std (standard carbohydrate-electrolyte solution)
Study: 30222805
Drug: Ranibizumab plus
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab plus deferred laser (0.5 mg)
Study: 30222805
Drug: Fluocinolone acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone acetonide (FAc) 0.2 μg/day
Study: 22990933
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition (control), n=15
Study: 19859788
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior group therapy (CBT)
Study: 18333863
Drug: Saquinavir (SQV;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir (SQV; 1200 mg t.i.d.)
Study: 23511711
Drug: Ketoconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (400 mg q.d.)
Study: 18333863
Drug: Ritonavir-boosted lopinavir
Normalized name: lopinavir / ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir-boosted lopinavir (LPV/r; 400 mg/100 mg b.i.d.)
Study: 18333863
Drug: Ritonavir-boosted saquinavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir-boosted saquinavir (SQV/r; 1000 mg/100 mg b.i.d.)
Study: 18333863
Drug: Low-dose ritonavir
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ritonavir (RTV; 100 mg b.i.d.)
Study: 18333863
Drug: Atazanavir (ATZ;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir (ATZ; 400 mg q.d.)
Study: 18333863
Drug: Ritonavir-boosted atazanavir
Normalized name: atazanavir and ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir-boosted atazanavir (ATZ/r; 300 mg/100 mg b.i.d.)
Study: 18333863
Drug: Ritonavir-boosted tipranavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir-boosted tipranavir (TPV/r; 500 mg/200 mg b.i.d.)
Study: 18333862
Drug: Maraviroc (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maraviroc (100 mg b.i.d.)
Study: 12401633
Drug: Epidural ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural ropivacaine 1.5 mg/kg with epinephrine 5 microg/mL
Study: 12401633
Drug: Epidural ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural ropivacaine 1.5 mg/kg without epinephrine (plain group)
Study: 10621575
Drug: Capital infusions
Normalized name: Lespedeza capitata flowering top extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capital infusions and up-front classes
Study: 7546757
Drug: C6 stellate
Normalized name: HYDROGENATED C6-20 POLYOLEFIN (100 CST)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C6 stellate ganglion nerve block with radiocontrast and local anesthetic (5 ml increments to 20 ml total volume)
Study: 7546757
Drug: C7 stellate
Normalized name: Mastocarpus stellatus
Approvals — FDA: no, EMA: no, PMDA: no
Description: C7 stellate ganglion nerve block with radiocontrast and local anesthetic (5 ml increments to 20 ml total volume)
Study: 2360541
Drug: 4.0 mg
Normalized name: LORAZEPAM 4.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 mg pyridoxine
Study: 2360541
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg pyridoxine
Study: 2360541
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg zinc
Study: 2360541
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg zinc
Study: 343182
Drug: Conventional practices
Normalized name: Practical Alchemy Purify and Protect Duo KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional practices (amniotomy and intravenous oxytocin infusion or oral prostaglandin therapy)
Study: 27908604
Drug: Phospholipid liposomal
Normalized name: Egg Phospholipids
DrugBank: Egg phospholipids (DB14233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phospholipid liposomal spray (Tears Again®) applied to one eye four times daily for two weeks.
Study: 27908604
Drug: Control eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control eye (no treatment).
Study: 26583954
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) - 10 sessions
Study: 23915015
Drug: Sertraline (SER)
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline (SER) - 50-200 mg/d
Study: 23915015
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received diabetes treatment as usual
Study: 21995387
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard adjuvant systemic therapy without zoledronic acid)
Study: 25935963
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg mifepristone
Study: 19187370
Drug: 24-hour interval
Normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour interval to misoprostol administration
Study: 19187370
Drug: 48-hour interval
Normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 48-hour interval to misoprostol administration
Study: 15186939
Drug: Ivermectin at
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin at 800 microg/kg given at 3-monthly intervals
Study: 15186939
Drug: Ivermectin at
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin at high doses (800 microg/kg)
Study: 19788472
Drug: Zolmitriptan 10
Normalized name: zolmitriptan 100 % MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan 10 mg
Study: 9453273
Drug: Dexfenfluramine 15
Normalized name: dexfenfluramine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexfenfluramine 15 mg
Study: 9453273
Drug: Lorazepam 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 1.25 mg
Study: 7876396
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg oral dose of metronidazole
Study: 7876396
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of 0.75% metronidazole intravaginal gel (37.5 mg metronidazole)
Study: 31356278
Drug: FOLFOX perioperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FOLFOX perioperative chemotherapy (4 cycles before surgery and 8 cycles after)
Study: 26780673
Drug: Individual schema
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual schema therapy (ST)
Study: 26780673
Drug: No-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment control condition (baseline phase)
Study: 18379232
Drug: Doripenem 500
Normalized name: doripenem 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doripenem 500 mg every 8 hrs via a 4‐hr intravenous infusion
Study: 18379232
Drug: Imipenem 500
Normalized name: imipenem 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem 500 mg every 6 hrs or 1000 mg every 8 hrs via 30‐ or 60‐min intravenous infusions